PAZO-OSTEO

NCT01759303 📎

Regimen

Experimental
Pazopanib 800 mg/d
Control
None (vs historical 4-month PFS benchmark ~12%)

Population

Metastatic osteosarcoma with lung metastases after standard chemotherapy

Key finding

Small underpowered study. Pazopanib landed in the same narrow 4-month PFS ~40-50% band as sorafenib/regorafenib/cabozantinib, consistent with a class effect of VEGFR-directed TKIs. Publication also a methodological lesson on RECIST in pulmonary-only osteo.

Source: PMID 35075361

Timeline

    Guideline citations

    • NCCN BONE (p.31)